169 related articles for article (PubMed ID: 16128647)
1. Implantable drug delivery systems (IDDS) after failure of comprehensive medical management (CMM) can palliate symptoms in the most refractory cancer pain patients.
Smith TJ; Coyne PJ
J Palliat Med; 2005 Aug; 8(4):736-42. PubMed ID: 16128647
[TBL] [Abstract][Full Text] [Related]
2. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival.
Smith TJ; Staats PS; Deer T; Stearns LJ; Rauck RL; Boortz-Marx RL; Buchser E; Català E; Bryce DA; Coyne PJ; Pool GE;
J Clin Oncol; 2002 Oct; 20(19):4040-9. PubMed ID: 12351602
[TBL] [Abstract][Full Text] [Related]
3. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM).
Smith TJ; Coyne PJ; Staats PS; Deer T; Stearns LJ; Rauck RL; Boortz-Marx RL; Buchser E; Català E; Bryce DA; Cousins M; Pool GE
Ann Oncol; 2005 May; 16(5):825-33. PubMed ID: 15817596
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of intrathecal drug delivery system for refractory cancer pain patients: a single tertiary medical center experience.
Lin CP; Lin WY; Lin FS; Lee YS; Jeng CS; Sun WZ
J Formos Med Assoc; 2012 May; 111(5):253-7. PubMed ID: 22656395
[TBL] [Abstract][Full Text] [Related]
5. Pain management, including intrathecal pumps.
Smith TJ; Swainey C; Coyne PJ
Curr Oncol Rep; 2004 Jul; 6(4):291-6. PubMed ID: 15161583
[TBL] [Abstract][Full Text] [Related]
6. Intrathecal Drug Delivery Systems for Refractory Pancreatic Cancer Pain: Observational Follow-up Study Over an 11-Year Period in a Comprehensive Cancer Center.
Carvajal G; Dupoiron D; Seegers V; Lebrec N; Boré F; Dubois PY; Leblanc D; Delorme T; Jubier-Hamon S
Anesth Analg; 2018 Jun; 126(6):2038-2046. PubMed ID: 29543644
[TBL] [Abstract][Full Text] [Related]
7. What is the evidence for implantable drug delivery systems for refractory cancer pain?
Smith TJ; Coyne P
Support Cancer Ther; 2004 Apr; 1(3):185-9. PubMed ID: 18628140
[TBL] [Abstract][Full Text] [Related]
8. Use of an implantable drug delivery system for refractory chronic sickle cell pain.
Smith TJ; Coyne PJ; Smith WR; Roberts JD; Smith V
Am J Hematol; 2005 Feb; 78(2):153-4. PubMed ID: 15682408
[TBL] [Abstract][Full Text] [Related]
9. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival.
Ripamonti C; Brunelli C
J Clin Oncol; 2003 Jul; 21(14):2801-2; author reply 2802-3. PubMed ID: 12860959
[No Abstract] [Full Text] [Related]
10. Myth and Truth in Opioid Consumption with Intrathecal Morphine Pump Implantation in Chronic Pain: A Retrospective Cohort Study with Claims Database in South Korea.
Yoo Y; Oh JH; Lee H; Choi H; Joo S; Han AH; Moon JY
Pain Med; 2023 Jan; 24(1):79-88. PubMed ID: 35881702
[TBL] [Abstract][Full Text] [Related]
11. Pain management, including intrathecal pumps.
Smith TJ; Swainey C; Coyne PJ
Curr Pain Headache Rep; 2005 Aug; 9(4):243-8. PubMed ID: 16004839
[TBL] [Abstract][Full Text] [Related]
12. Treatment of medically refractory cancer pain with a combination of intrathecal neuromodulation and neurosurgical ablation: case series and literature review.
Bentley JN; Viswanathan A; Rosenberg WS; Patil PG
Pain Med; 2014 Sep; 15(9):1488-95. PubMed ID: 24931480
[TBL] [Abstract][Full Text] [Related]
13. Audit of intrathecal drug delivery for patients with difficult-to-control cancer pain shows a sustained reduction in pain severity scores over a 6-month period.
Mitchell A; McGhie J; Owen M; McGinn G
Palliat Med; 2015 Jun; 29(6):554-63. PubMed ID: 25690600
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of intrathecal drug delivery system for intractable pain in advanced malignancies: A prospective cohort study.
Zheng S; He L; Yang X; Li X; Yang Z
Medicine (Baltimore); 2017 Mar; 96(11):e6354. PubMed ID: 28296770
[TBL] [Abstract][Full Text] [Related]
15. Intrathecal Drug Delivery Systems for Cancer Pain Control: Insights on Current Contemporary Practices in the US.
Goel V; Kumar V; Blaes A; Gulati A
Neuromodulation; 2023 Aug; 26(6):1256-1262. PubMed ID: 37318432
[TBL] [Abstract][Full Text] [Related]
16. Long-term intrathecal drug administration for chronic nonmalignant pain.
Duarte RV; Raphael JH; Sparkes E; Southall JL; LeMarchand K; Ashford RL
J Neurosurg Anesthesiol; 2012 Jan; 24(1):63-70. PubMed ID: 21904220
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive consensus based guidelines on intrathecal drug delivery systems in the treatment of pain caused by cancer pain.
Deer TR; Smith HS; Burton AW; Pope JE; Doleys DM; Levy RM; Staats PS; Wallace MS; Webster LR; Rauck RL; Cousins M;
Pain Physician; 2011; 14(3):E283-312. PubMed ID: 21587338
[TBL] [Abstract][Full Text] [Related]
18. Intrathecal drug delivery system (IDDS) for cancer pain management: a review and updates.
Upadhyay SP; Mallick PN
Am J Hosp Palliat Care; 2012 Aug; 29(5):388-98. PubMed ID: 22089523
[TBL] [Abstract][Full Text] [Related]
19. A cost utilization analysis of intrathecal therapy for refractory cancer pain: identifying factors associated with cost benefit.
Brogan SE; Winter NB; Abiodun A; Safarpour R
Pain Med; 2013 Apr; 14(4):478-86. PubMed ID: 23461787
[TBL] [Abstract][Full Text] [Related]
20. SynchroMed II intrathecal pump memory errors due to repeated magnetic resonance imaging.
Kosturakis A; Gebhardt R
Pain Physician; 2012; 15(6):475-7. PubMed ID: 23159963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
